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Abstract—As metabolic pathways are highly variable among
different patients, then an accurate and continuous monitoring
of the personal response to drug treatments is essential especially
with critical medications, e.g. anesthetic and anti-cancer cocktails.
Currently, for anesthesia monitoring, there are no fully mature
point-of-care bio-sensing systems. Indeed, it is still evaluated by
mathematical models and with indirect parameters like Bispectral
Index, which can not provide the actual concentration in blood.
The aim of this paper is to investigate solutions for developing
a portable system able to monitor simultaneously several different
drugs. For this purpose, Cyclic Voltammetries with an anesthetic
product and therapeutic compounds were performed for the
validation of the system. A multichannel potentiostat has been
realized with Off-The-Shelf Components (COTS). Then, results
from electrochemical acquisitions on GC SPEs show that the
proposed circuitry is suitable for this aim and they prove its high
flexibility to develop portable systems for continuous monitoring
of anesthetics and therapeutic compounds.
I. INTRODUCTION
Personalized therapy offers the opportunity to increase ther-
apeutic efficacy of drugs by targeting the right dosage for each
patient and, at the same time, by decreasing toxicity due to
overdosing [1]. In this context, Therapeutic Drug Monitoring
(TDM) is crucial for difficult-to-manage and critical medica-
tions, like anticancer drugs or anesthetics [2]. The aim of this
clinical practice is to determine the drug dosage by maintaining
the plasma or blood concentration in a targeted therapeutic
range to optimize the efficacy in patients’ treatments [3].
In case of anesthesia an accurate balanced delivery of
several compounds, including anesthetics, analgesics and mus-
cle relaxants is required to achieve a certain target plasma
concentration able to assure appropriate sedation and to avoid
intoxication or awareness. The effect of anesthesia on patient
is expressed as the Depth Of Anesthesia (DOA) which is a
very challenging parameter to estimate. Traditional methods
to evaluate this crucial parameter are based on the observation
of several physiological symptoms such as patient’s heart rate
and blood pressure [4]. However, these parameters varies a
lot depending on the type of surgery [5] and the patient,
then they are inadequate [6] and with very poor predictive
value [7]. Algorithms based on Bispectral Index (BIS) are
actually used in surgery to monitor the DOA of the patient.
The BIS is a weighted sum of several electroencephalographic
(EEG) parameters [8] and its value decreases linearly with the
increasing of the DOA. Unfortunately, also these techniques
return wrong estimations in clinical situations due to abnormal
EEG patterns or to different anesthetics or to interferences by
other drugs [9]. Then, a system able to balance the DOA by
administering drugs on the base of their actual concentration in
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Fig. 1. Conceptual feedback loop system. It consists of three parts: the Target
Controlled Infusion (TCI) pump for the anesthesia delivery, the hardware
system for continuous monitoring of anesthetics in patient’s blood and the
anesthesiologist who regulates the infusion pump according to the actual
concentration. This closed loop allows the anesthesiologist to have under
control the real depth of anesthesia of the patient.
patient’s blood could be really attractive for better practice in
anesthesiology. The diagram in Fig. 1 presents the concept
of a feedback system for anesthesia delivery based on the
continuous monitoring of anesthetics in the blood. In this
system there are two main sub-systems: the Target-Controlled
Infusion (TCI) pump for anesthesia, already largely used in
surgical practices, and the real-time monitoring system for the
evaluation of anesthetics concentration in patient’s blood. The
second block allows the anesthesiologist to adjust the infusion
rate if necessary, based on real measurements in patient’s
blood.
Currently, the measurement of drugs concentration in blood
is performed using techniques such as mass spectrometry [10],
liquid or gas chromatography or immunoassay [11]. However,
all of them are not technically suitable for portable on-
line continuous monitoring. Electrochemical biosensors offer,
instead, a suitable method for the real-time monitoring in blood
since direct electrochemistry does not require the renewal of
the electrode surface between measurements meanwhile the
selectivity of the electrode could be enhance by the use of a
proper membrane [12].
Normally, electrochemical measurement unit setup consists
of a sensing part in direct contact with the analyzed solution
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Fig. 2. Sketch of electrochemical cells that interface with the multichannel
potentiostat system blocks: micro-controller that drives the voltage generation
circuits and receives amperometric values from the readout circuits.
and an electronic part that controls the sensor. The sensing
part is usually a three-electrodes (Working, Reference and
Counter Electrodes - WE, RE, CE) cell that interfaces with
the electronic readout through a potentiostat [13]. Hence, the
potentiostat plays a pivotal role by ensuring a constant potential
(∆V ) between RE and WE [14] and by collecting current
through CE so that reduction and oxidation occurs on the
surface of WE [15]. The cell potential between RE and WE
(∆V ) is distinct for each analyte, allowing specific compound
recognition while the current through CE permits the quan-
tification of such analyte. Many electrochemical techniques
are feasible, but Cyclic Voltammetry (CV) is the most suitable
for detecting multiple compounds at the same time [16]. A
linear-sweep potential ramp within a specific window range of
values is applied for performing a CV and the output current
is continuously monitored.
Over the years, several integrated circuit potentiostats have
been developed for chemicals and metabolites detection in
[17], [18] but very few are applicable to drugs monitoring
[19]. Therefore, more research is required for adopting electro-
chemical techniques in DOA monitoring. Moreover, a system
able to perform simultaneous monitoring of multiple targets
is recommended for the several compounds in the anesthetic
cocktail.
In this paper we present a new portable system designed
to detect several different compounds in a simultaneous way
thanks to the independence of the electrochemical cells on
the board. We tested the system by performing CVs with an
anesthetic, propofol, an analgesic, paracetamol and an anti-
cancer drug, etoposide. It was considered, indeed, the case
in which the patient under anesthesia, is also subjected to
other therapeutic treatments, which is very common case.
The paper is organized as follow: Section II describes the
system architecture, Section III collects the procedure and the
solutions used for the validation of the system. The validation
of the system is presented in Session IV, and, finally, Session
V concludes the paper.
II. SYSTEM ARCHITECTURE
The proposed system, in Fig. 2, consists of three inde-
pendent electrochemical cells each one in the three-electrodes
configuration. The sensing part interfaces with a potentiostat
realized using COTS electronic circuit. The circuit, realized
on a Printed Circuit Board (PCB) in Fig. 3, also implements
three independent amperometric sensing channels with voltage
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Fig. 3. Printed Circuit Board developed for CV and CA measurements with
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Fig. 4. Detailed architecture of the potentiostatic circuit.
generators and readout circuits for each electrochemical cell.
This architecture, then, is able to perform all the measurements
with the same front-end enabling the simultaneous monitoring
of three different compounds without losing data by switching
among them with multiplexing techniques and avoiding any
cross-talk through the cells since they are totally independent.
The portability of the system is based on small dimensions
16×6 cm and low power supply 3.3 V, which is reachable by
a common battery.
Fig. 4 shows the schematic of the multichannel potentiostat
in grounded-WE configuration and arranged for amperometric
readout, since the signal which derives from CV is a current.
This current signal derives from the oxidation or reduction of
the analyte at the WE surface and it is strictly related to the
presence and the concentration of the analyte itself. The basic
circuit that realizes the potentiostat features consists of two
main parts: (i) the micro-controller (ATxmega32E5 by Atmel
AVR XMEGA) that controls the voltage between WE and RE
through a 10-bit Digital-to-Analog Coverter (DAC, MCP4911
by Microchip Technology Inc.) and through a control amplifier,
and (ii) the transimpedance amplifier (TIA): able to convert the
value of the current flowing inside the electrochemical cell into
a voltage by the very well-known relation V out = −Rf · Icell.
This analog voltage value is then digitalized by the 12-bit
Analog-to-Digital Converter (ADC) of the micro-controller.
In particular, the DAC output is buffered with a low pre-
cision CMOS amplifier that allows low offset voltage and
low noise. The DAC drives capacitive loads without any
oscillations, hence, it is suitable for piloting electrochemical
cells. Furthermore, the DAC was chosen serial to allow an
easier connectivity and programmability. The design of the
ADC in the microcontroller depends on pipeline technology
which promotes high speed with 12 bit resolution and high
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bandwidth up to 1 MHz. Both the voltage generation and
the readout circuits are repeated three times to control and
read three different electrochemical cells at the same time,
as shown in Fig. 4. Therefore, the system can be used to
measure simultaneously three sensors by allocating, on the
same platform, independent channels for every substance.
A. Voltage generation circuit
A multiple Direct Digital Synthesizer (DDS) is realized
to generate the linear-sweep potential ramps for each electro-
chemical cell for performing CVs. Each waveform generator
is realized by the microcontroller that sends an increasing
or decreasing digital value to the specific 10-bit DAC which
converts it in an analog voltage. Positive and negative potential
values are applied to the WEs thanks to an offset (V cc/2)
at the non-inverting input of the TIAs, as shown in Fig. 4.
The communication between the microcontroller and the DAC
is based on SPI interface. The analog value from the DAC
is applied to the sensing cell through a control amplifier
that offers high input resistance and zero current suitable for
connecting the RE.
B. Different amplifier topologies
The circuit realizes CV and offers different transimpedance
topologies as readouts. To provide a reconfigurable and flexible
system, two readout configurations are realized: one TIA
with fixed transimpedance gain of 10kΩ and the other one
with two stages of amplification, first stage with fixed tran-
simpedance gain and another amplification stage in cascade.
This second stage amplification contains a programmable
digital potentiometer TPL0102 by Texas Instruments with
256 wiper positions and an end-to-end resistance of 100kΩ.
Then, the total gain of this second readout circuit will be:
GTIA = Rfixed · Gvariable where Rfixed is 10kΩ and Gvariable,
given by the ratio RH/RL, is at maximum 100k, Fig. 4. We
set the readout configuration of the circuit before starting
the measurements, then the characteristics of the switches are
negligible.
The flexibility and feasibility of the circuit is given by the
separate channels for each analyte so that it is possible to set
the suitable gain different for each of them.
When comparing the two readout circuit configurations, the
fixed gain TIA results in better signal to noise ratio (S/N) in
comparison with the variable-resistor TIA. This is due to the
fact that the digital potentiometer introduces some noise that,
added to the noise on the input signal from the sensing cell,
is amplified by the second stage.
Finally, it is also important to notice from the schematic in
Fig. 4 that, throughout the design, the circuit is virtually
grounded at half value of the power supply (Vcc/2) to al-
low positive and negative voltages therefore implementing a
grounded-WE configuration.
III. MATERIALS AND METHODS
A. Chemicals
2,6-Diisopropylphenol (propofol) was purchased from TCI
(Switzerland) and prepared first as a 5 mM stock solution
in 0.1 M NaOH. Instead, etoposide and paracetamol were
both purchased in powder from Sigma-Aldrich (Switzerland).
Etoposide 30 mM stock solution was obtained by dissolving
15 mg of powder in 1 ml Dimetil Sulfoxide, also provided
by Sigma Aldrich. Finally 5 mg of paracetamol powder were
dissolved in 1 ml 1 x Phosphate Buffered Saline (PBS, pH
7.4) to obtain 30 mM stock solution.
B. Electrochemical Measurements
Since both the therapeutic compounds and the anesthetic
are electroactive, direct CVs were performed in hydrodynamic
condition (stirring velocity 140 rpm) with the here presented
circuit. Glassy Carbon (GC) Screen Printed Electrode (SPE)
by Methrom (working electrode diameter 4 mm) were adopted
as electrochemical cells and connected to our PCB for mea-
surements. All experiments were carried out in a 1 x PBS (pH
7.4) as supporting electrolyte. All the data from measurements
has been post-processed with filtering. A Finite Impulse Re-
sponse (FIR) Low Pass Filter (LPF), with the software Igor
Pro 6.03A2, has been applied in order to eliminate the high
frequency noise since electrochemical signal is presents only
at low frequencies.
IV. SYSTEM VALIDATION
Voltammograms reported in Fig. 5 were acquired with the
system in a potential range between -0.8 V and +1.7 V with
a scan rate of 100 mV/s and in stirring conditions (velocity
of 140 rpm). The SPEs, connected to the developed board,
were dipped each one in a different 10 ml of 1 x PBS solution
(pH 7.4), and tested with three different concentrations for
each compound. The traces in the charts unequivocally confirm
a good performance of the architecture proposed in Fig. 4.
Etoposide was tested at 400 mM, 800 mM and 900 mM,
propofol at 450 mM, 500 mM and 530 mM, and paracetamol
at 300 mM, 500 mM and 700 mM. In each graph characteristic
peaks of each analyte can be identified. Moreover, an increase
of the traces occurs for each subsequent concentration. It is
possible to observe that, in case of propofol, the trace slightly
increases between 500 mM and 530 mM. This is due to the
well known problem of fouling that creates an insulating layer
on WE surface which decreases the output signal. This problem
is usually solved by adding a PVC membrane on the WE
surface, as in [20].
In any case, data compare quite well with those published in
literature on the same redox reactions [21], [22], [23].
V. CONCLUSION
In this paper, the design, the prototyping and the validation
of a portable multichannel potentiostat for the detection of
multiple and different drugs is presented. Very different targets,
like an anesthetic, propofol, an anti-cancer drug, etoposide
and an analgesic, paracetamol, are taken in consideration for
proving the flexibility of the circuit. The portability is provided
by the small dimensions (16 × 6 cm) and low power supply
(3.3 V). CVs were performed with the developed circuit using
GC SPEs. All the data from electrochemical acquisitions for
all the considered analytes have been shown.
More in general, since other anesthetics, such as midazolam
and fentanyl are detectable by direct CV [24], [25], this
architecture, proved here for propofol monitoring, will be also
used for them. Hence, an important step to realize monitoring
of anesthetics during surgery and monitoring of therapeutic
compounds in Intensive Care Units (ICUs) is achieved.
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